NMRA
Price:
$1.51
Market Cap:
$279.78M
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiat...[Read more]
Industry
Biotechnology
IPO Date
2023-09-15
Stock Exchange
NASDAQ
Ticker
NMRA
According to Neumora Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current Current Ratio is 5.09. This represents a change of -28.13% compared to the average of 7.09 of the last 4 quarters.
The mean historical Current Ratio of Neumora Therapeutics, Inc. Common Stock over the last ten years is 12.91. The current 5.09 Current Ratio has changed 3.85% with respect to the historical average. Over the past ten years (40 quarters), NMRA's Current Ratio was at its highest in in the September 2021 quarter at 21.15. The Current Ratio was at its lowest in in the March 2021 quarter at 0.
Average
12.91
Median
16.37
Minimum
0
Maximum
20.69
Discovering the peaks and valleys of Neumora Therapeutics, Inc. Common Stock Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Current Ratio = 20.69
Minimum Annual Increase = -44.83%
Minimum Annual Current Ratio = 0
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 5.87 | -44.13% |
| 2024 | 10.51 | -44.83% |
| 2023 | 19.05 | 16.34% |
| 2022 | 16.37 | -8.30% |
| 2021 | 17.85 | -13.70% |
| 2020 | 20.69 | Infinity% |
The current Current Ratio of Neumora Therapeutics, Inc. Common Stock (NMRA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
11.81
5-year avg
13.93
10-year avg
12.91
Neumora Therapeutics, Inc. Common Stock’s Current Ratio is less than RAPT Therapeutics, Inc. (12.04), less than Bicycle Therapeutics plc (12.66), greater than Omeros Corporation (3.03), greater than ADC Therapeutics S.A. (4.09), less than Lexicon Pharmaceuticals, Inc. (18.79), less than Alumis Inc. Common Stock (7.51), less than Fulcrum Therapeutics, Inc. (34.33), less than 4D Molecular Therapeutics, Inc. (9.34), less than Prothena Corporation plc (10.43), less than Autolus Therapeutics plc (5.80),
| Company | Current Ratio | Market cap |
|---|---|---|
| 12.04 | $959.26M | |
| 12.66 | $277.58M | |
| 3.03 | $744.02M | |
| 4.09 | $138.64M | |
| 18.79 | $892.83M | |
| 7.51 | $2.89B | |
| 34.33 | $200.21M | |
| 9.34 | $504.99M | |
| 10.43 | $467.51M | |
| 5.80 | $401.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neumora Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neumora Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Neumora Therapeutics, Inc. Common Stock's Current Ratio?
How is the Current Ratio calculated for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the highest Current Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the 3-year average Current Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)?
What is the 5-year average Current Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA)?
How does the current Current Ratio for Neumora Therapeutics, Inc. Common Stock (NMRA) compare to its historical average?